Nordea Investment Management AB acquired a new position in USANA Health Sciences Inc. (NYSE:USNA) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 5,092 shares of the company’s stock, valued at approximately $567,000.

Several other hedge funds also recently bought and sold shares of USNA. Norges Bank bought a new stake in USANA Health Sciences during the fourth quarter worth about $8,981,000. Acadian Asset Management LLC increased its stake in USANA Health Sciences by 1.8% in the first quarter. Acadian Asset Management LLC now owns 206,936 shares of the company’s stock worth $25,127,000 after buying an additional 3,614 shares in the last quarter. Parametrica Management Ltd bought a new stake in USANA Health Sciences during the first quarter worth about $410,000. Teachers Advisors Inc. increased its stake in USANA Health Sciences by 30.6% in the first quarter. Teachers Advisors Inc. now owns 87,383 shares of the company’s stock worth $10,610,000 after buying an additional 20,496 shares in the last quarter. Finally, Prudential Financial Inc. increased its stake in USANA Health Sciences by 48.3% in the first quarter. Prudential Financial Inc. now owns 31,317 shares of the company’s stock worth $3,802,000 after buying an additional 10,199 shares in the last quarter. 41.97% of the stock is owned by institutional investors.

USANA Health Sciences Inc. (NYSE:USNA) traded down 0.19% during mid-day trading on Friday, reaching $136.20. 44,958 shares of the company’s stock traded hands. The stock has a 50-day moving average price of $136.16 and a 200-day moving average price of $123.82. USANA Health Sciences Inc. has a 12-month low of $92.00 and a 12-month high of $148.15. The stock has a market capitalization of $1.64 billion, a PE ratio of 17.95 and a beta of 1.16.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings data on Tuesday, July 26th. The company reported $2.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.05 by $0.02. The firm earned $258.50 million during the quarter, compared to analysts’ expectations of $256.66 million. USANA Health Sciences had a net margin of 10.07% and a return on equity of 34.15%. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period in the prior year, the company posted $1.92 earnings per share. Equities research analysts expect that USANA Health Sciences Inc. will post $8.10 EPS for the current year.

USNA has been the subject of a number of research analyst reports. DA Davidson lifted their price objective on shares of USANA Health Sciences from $135.00 to $150.00 and gave the stock a “neutral” rating in a report on Thursday, July 28th. Zacks Investment Research raised shares of USANA Health Sciences from a “hold” rating to a “strong-buy” rating and set a $158.00 price objective for the company in a report on Saturday, July 30th. Two analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. USANA Health Sciences presently has an average rating of “Buy” and a consensus price target of $149.11.

In other news, Director Gilbert A. Fuller sold 859 shares of the stock in a transaction on Monday, August 1st. The shares were sold at an average price of $137.07, for a total value of $117,743.13. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert Auciaux sold 2,317 shares of the stock in a transaction on Tuesday, August 23rd. The stock was sold at an average price of $138.79, for a total transaction of $321,576.43. Following the completion of the sale, the director now directly owns 2,317 shares of the company’s stock, valued at $321,576.43. The disclosure for this sale can be found here. 57.00% of the stock is currently owned by insiders.

About USANA Health Sciences

USANA Health Sciences, Inc develops and manufactures science-based nutritional and personal care products. It operates as a direct selling company in approximately two geographic regions: Americas and Europe, and Asia Pacific, which includes approximately three sub-regions: Southeast Asia Pacific, Greater China and North Asia.

5 Day Chart for NYSE:USNA

Want to see what other hedge funds are holding USNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for USANA Health Sciences Inc. (NYSE:USNA).

Receive News & Ratings for USANA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.